Palmieri, Diane Smith, Quentin R. Lockman, Paul R. Bronder, Julie Gril, Brunilde Chambers, Ann F. Weil, Robert J. Steeg, Patricia S.
Verschenen in:
Breast disease
Paginering:
Jaargang 26 (2007) nr. 1 pagina's 139-147
Jaar:
2007-04-23
Inhoud:
Central nervous system or brain metastases traditionally occur in 10–16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2^+ or of the basal phenotype. Treatment typically includes whole brain irradiation, or either stereotactic radiosurgery or surgery with whole brain radiation, resulting in an ∼ 20% one year survival. The blood-brain barrier is a formidable obstacle to the delivery of chemotherapeutics to the brain. Mouse experimental metastasis model systems have been developed for brain metastasis using selected sublines of human MDA-MB-231 breast carcinoma cells. Using micron sized iron particles and MRI imaging, the fate of MDA-MB-231BR cells has been mapped: Approximately 2% of injected cells form larger macroscopic metastases, while 5% of cells remain as dormant cells in the brain. New therapies with permeability for the blood-brain barrier are needed to counteract both types of tumor cells.